Drug used for another purpose shows promising results in treating severe cases of COVID-19 pneumonia.

A drug used for cystic fibrosis shows promise in improving outcomes for severe COVID-19 pneumonia patients.

Dornase alfa, a drug commonly used to treat cystic fibrosis, showed promising results in improving outcomes for patients with severe COVID-19 pneumonia.
The drug was found to reduce hyper-inflammation in COVID-19 pneumonia patients, which can lead to tissue damage and death.
Patients treated with dornase alfa experienced a 33% reduction in systemic inflammation compared to those who did not receive the drug.
The next steps include conducting larger clinical trials to confirm the safety and efficacy of dornase alfa for treating severe COVID-19 pneumonia.
Researchers are optimistic about the potential of dornase alfa to treat other respiratory infections, such as influenza or bacterial pneumonia.

Study reveals dangerous microbes found in 7 billion tons of plastic waste